60
Participants
Start Date
October 26, 2020
Primary Completion Date
March 30, 2024
Study Completion Date
September 30, 2025
single dose of CNCT19
Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
Institute of Hematology & Blood Diseases Hospital, Tianjin
RECRUITING
Beijing Boren Hospital, Beijing
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Xinqiao Hospital of TMMU, Chongqing
RECRUITING
Guangdong Provincial Peoples' Hospital, Guangzhou
RECRUITING
SunYat-Sen University Cancer Center, Guangzhou
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Tongji Hospital, Tongji Medical College of HUST, Wuhan
RECRUITING
Qilu Hospital of Shandong University, Jinan
RECRUITING
Tongji Hospital of Tongji University, Shanghai
RECRUITING
West China Hospital，Sichuan University, Chengdu
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
The First Affiliated Hospital, Zhejiang University school of Medicine, Hangzhou
Lead Sponsor
Juventas Cell Therapy Ltd.
INDUSTRY